Interpreting the Findings From the Recent PCSK9 Monoclonal Antibody Cardiovascular Outcomes Trials

The recent development of monoclonal antibodies targeted to proprotein convertase subtilisin/kexin type 9 (PCSK9), e.g., PCSK9 inhibitors has revolutionized the landscape of lipid management. Many clinical trials assessing this class have demonstrated remarkable and consistent reductions in low-dens...

Täydet tiedot

Tallennettuna:
Bibliografiset tiedot
Julkaisussa:Front Cardiovasc Med
Päätekijät: Wong, Nathan D., Shapiro, Michael D.
Aineistotyyppi: Artigo
Kieli:Inglês
Julkaistu: Frontiers Media S.A. 2019
Aiheet:
Cardiovascular Medicine
Linkit:https://ncbi.nlm.nih.gov/pmc/articles/PMC6414420/
https://ncbi.nlm.nih.gov/pubmed/30895178
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.3389/fcvm.2019.00014
Tagit: Lisää tagi
Ei tageja, Lisää ensimmäinen tagi!

Samankaltaisia teoksia